NSCLC: sarcopenia predicts poor postresection OS in meta-analysis

  • Deng HY & al.
  • Eur J Surg Oncol
  • 15 Oct 2018

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Sarcopenia is an independent predictor of poor 5-year OS after the surgical resection of NSCLC.

Why this matters

  • Studies of the role of sarcopenia in predicting the prognosis of patients with NSCLC have yielded conflicting results.

Study design

  • Meta-analysis of 6 cohort studies with 1213 patients with NSCLC with (n=422) or without (n=791) sarcopenia.
  • Funding: None disclosed.

Key results

  • Patients with NSCLC with sarcopenia had a significantly lower 5-year OS than those without after surgical resection (61.1% vs 74.2%; random effects: risk ratio [RR], 1.63; 95% CI, 1.13-2.33).
  • No significant difference between groups in 5-year DFS (random effects: RR, 1.14; 95% CI, 0.59-2.17), but that analysis included only 3 studies with 557 patients.
  • Sarcopenia was an independent predictor of poor OS in patients with NSCLC after surgical resection (random effects: HR, 2.85; 95% CI, 1.67-4.86).
  • On analysis by disease stage, sarcopenia was a significant predictor of poor OS in patients with stage I NSCLC (HR, 4.68; 95% CI, 2.76-7.94) and in patients with all stages of NSCLC (HR, 1.71; 95% CI, 1.21-2.41).

Limitations

  • Heterogeneity among included studies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit